• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (OP: PMBHF )

    N/A UNCHANGED
    Last Price Updated: 9:46 AM EST, Jan 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.1200
    Today's Range N/A - N/A
    52wk Range 0.0316 - 0.1374
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
    Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
    Via Benzinga
    Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
    Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  
    Via Benzinga

    Performance

    More News

    Read More
    PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
    From PharmAla Biotech
    Via GlobeNewswire
    Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
    Via Benzinga
    PharmAla Begins Trading on OTCQB
    From PharmAla Biotech
    Via GlobeNewswire
    Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
    Via Benzinga
    Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
    Via Benzinga
    PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment
    Via Benzinga
    PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
    From PharmAla Biotech
    Via GlobeNewswire
    Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
    Via Benzinga
    Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
    Via Benzinga
    PharmAla's Australian JV Cortexa Orders First Commercial MDMA & Psilocybin Shipment
    Via Benzinga
    Life Science Investor Forum: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Science Investor Forum Agenda Announced for June 22nd
    From Virtual Investor Conferences
    Via GlobeNewswire
    MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
    Via Benzinga
    Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M
    Via Benzinga
    Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
    Via Benzinga
    USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
    From PharmAla Biotech
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.